🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in South Korea / NCT06977347
Starting soon Not applicable

Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

NCT06977347 · tracked via the Priya Life Science South Korea tracker
Sponsor
CHOSEOK YOON
Phase
Not applicable
Started
2025-06-15
Last updated
2025-05-18

Condition(s) studied

Severe Community-acquired Pneumonia (sCAP)

Investigational drug(s) / intervention(s)

Piperacillin/Tazobactam →Piperacillin/tazobactam + LevofloxacinAll Piperacillin-tazobactam trials (8) →All Levofloxacin trials (11) →

Piperacillin/Tazobactam: Piperacillin/tazobactam: 4.5g IV q6h (over 3h)

Piperacillin/tazobactam + Levofloxacin: Piperacillin/tazobactam: 4.5g IV q6h (over 3h) \+ Levofloxacin 750mg IV q24h (over 30min)

Study summary

This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and combination therapy with piperacillin/tazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
* Inclusion Criteria: * Adult patients aged 19 years or older who visited the emergency department and were hospitalized. * Findings consistent with pneumonia diagnosis, meeting all of the following criteria: * Radiologic evidence of pulmonary infiltration on chest X-ray or chest CT. * At least two or more of the following clinical signs: i) Body temperature ≥38°C or \<36°C ii) White blood cell count ≥11,000/µL or \<4,000/µL iii) Presence of purulent sputum or bronchial secretions * Within 24 hours of admission, the patient meets one major criterion or three minor criteria according to ATS/IDSA classification: * Major criteria: i) Invasive mechanical ventilation ii) Use of vasopressors (vasopressor-dependent septic shock) * Minor criteria: i) Respiratory rate ≥30 breaths/min ii) PaO2/FiO2 ≤ 250 iii) Multilobar infiltrates iv) Confusion or disorientation v) BUN ≥20 mg/dL vi) WBC \<4,000/mm³ vii) Platelet count \<100,000/mm³ viii) Hypothermia (temperature \<36°C) ix) Hypotension requiring aggressive fluid resuscitation * Exclusion Criteria: * Transferred from another hospital after \>48 hours of hospitalization * Died within 72 hours of hospital admission * Transferred to another hospital within 14 days of admission * Pneumonia occurring after \>48 hours of mechanical ventilation, including home ventilators * Detection of influenza or SARS-CoV-2 virus within 7 days of hospitalization * Identified non-pneumonia infection requiring antibiotics within 72 hours of admission * Detection of piperacillin/tazobactam-resistant Enterobacterales, Pseudomonas spp., or Acinetobacter spp. in respiratory or blood cultures within the past 90 days * Antibiotic-related adverse events observed within 72 hours of assigned treatment, requiring discontinuation or change of antibiotics

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hanyang University Seoul Hospital Seoul Seoul
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06977347 on ClinicalTrials.gov ↗ ← All trials in South Korea